A. Cox

C. Der, K. Kato, R. Khosravi‐Far, 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Nicole M. Baker, E. Petricoin, D. Esposito, 2019, Cancer discovery.

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

James M. McFarland, Laura E. Herring, Yingyao Zhou, 2020, Cell reports.

Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity.

C. Der, A. Cox, 1991, Cancer cells.

ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma

C. Der, A. Cox, N. Thomas, 2016, Molecular Cancer Research.

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.

E. Petricoin, C. Der, K. Wood, 2022, Molecular cancer therapeutics.

Ras ( CXXX ) and Rab ( CClCXC ) Prenylation Signal Sequences Are Unique and Functionally Distinct *

C. Der, R. Khosravi‐Far, R. Lutz, 2001 .

Analysis of Ras protein expression in mammalian cells.

C. Der, A. Cox, P. A. Solski, 1995, Methods in enzymology.

L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases.

D. Brenner, J. Westwick, A. Cox, 1997, The American journal of physiology.

Protein localization: Can too much lipid glue stop Ras?

A. Cox, 2010, Nature chemical biology.

Farnesyltransferase Inhibitors: Biological Considerations for Future Therapeutics

A. Cox, L. Toussaint, 2002 .

Novel determinants of H-Ras plasma membrane localization and transformation.

C. Der, A. Cox, B. Willumsen, 1996, Oncogene.

Isoprenoid modification of rab proteins terminating in CC or CXC motifs.

C. Der, R. Khosravi‐Far, R. Lutz, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors.

E. Petricoin, K. Wennerberg, C. Der, 2021, Cancer research.

R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.

C. Der, A. Cox, T. Brtva, 1994, Oncogene.

Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration*

G. Bepler, S. Nicosia, C. Der, 2013, The Journal of Biological Chemistry.

Radiosensitization of EGFR/HER2 positive pancreatic cancer is mediated by inhibition of Akt independent of Ras mutational status

J. Tepper, B. Calvo, J. M. Shields, 2010 .

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.

C. Der, A. Cox, Priya S. Hibshman, 2022, Advances in cancer research.

Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function.

R. L. Johnson, C. Der, R. Johnson, 2001, Methods in enzymology.

Phosphorylation by Protein Kinase Cα Regulates RalB Small GTPase Protein Activation, Subcellular Localization, and Effector Utilization*

C. Der, J. Yeh, N. Mitin, 2012, The Journal of Biological Chemistry.

Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.

M. Barbacid, C. Der, B. Seizinger, 1995, Oncogene.

Biological assays for cellular transformation.

C. Der, A. Cox, 1994, Methods in enzymology.

Functional and biological heterogeneity of KRASQ61 mutations

E. Petricoin, C. Der, N. Rashid, 2022, Science Signaling.

Regulation of Rnd3 Localization and Function By PKC α -Mediated Phosphorylation

Keller, C. Der, A. Ridley, 2010 .

Transcriptional activation analysis of oncogene function.

C. Hauser, C. Der, A. Cox, 1994, Methods in enzymology.

A nanotube based electron microbeam cellular irradiator for radiobiology research.

Sha X. Chang, O. Zhou, A. Cox, 2008, The Review of scientific instruments.

The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.

D. Brenner, C. Der, J. Westwick, 1994, The Journal of biological chemistry.

R-Ras C-terminal sequences are sufficient to confer R-Ras specificity toH-Ras

A. Cox, M. Hansen, M. Ginsberg, 2002, Oncogene.

Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy.

Ronald C. Chen, A. Cox, M. Napier, 2011, ACS nano.

K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif

A. Cox, K. Haigis, J. Fiordalisi, 2015, Proceedings of the National Academy of Sciences.

Filling in the GAPs in understanding RAS: A newly-identified regulator increases the efficacy of a new class of targeted anti-RAS drugs

C. Der, A. Cox, 2021 .

C. Der, A. Cox, Timothy D. Martin, 2010, International journal of radiation oncology, biology, physics.

CYTOSOLIC GTP-BOUND Ras EFFECTOR DOMAIN MUTANTS THAT INHIBIT Ras SIGNALING AND TRANSFORMATION AND ENHANCE CELL ADHESION*

A. Cox, J. Fiordalisi, S. Holly, 2002 .

Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1.

A. Pellicer, Theresa M. Grana, A. Cox, 2003, Nature.

Rab1b regulates vesicular transport between the endoplasmic reticulum and successive Golgi compartments

C. Der, R. Khosravi‐Far, W. Balch, 1991, The Journal of cell biology.

Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.

Karen N Conneely, Leslie B Gordon, Francis S Collins, 2005, Proceedings of the National Academy of Sciences of the United States of America.

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Laura E. Herring, G. Hostetter, K. Wennerberg, 2018, Cancer cell.

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

E. Petricoin, C. Der, C. Kuo, 2021, Cell reports.

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

C. Der, A. Cox, 1997, Biochimica et biophysica acta.

Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells

A. Cox, N. Ratner, J. Kamholz, 2004, Oncogene.

Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification*

C. Der, N. Mitin, P. Roberts, 2008, Journal of Biological Chemistry.

R-Ras Signals through Specific Integrin α Cytoplasmic Domains to Promote Migration and Invasion of Breast Epithelial Cells

P. Keely, A. Cox, L. Parise, 1999, The Journal of cell biology.

Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA

C. Der, A. Cox, K. Lim, 2009, Molecular and Cellular Biology.

Farnesyltransferase inhibitors: potential role in the treatment of cancer.

A. Cox, A D Cox, 2001, Drugs.

Single Cell Ras-GTP Analysis Reveals Altered Ras Activity in a Subpopulation of Neurofibroma Schwann Cells but Not Fibroblasts*

R. Atit, A. Cox, N. Ratner, 2000, The Journal of Biological Chemistry.

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Laura E. Herring, E. Petricoin, K. Wennerberg, 2020, Cell reports.

Rho GTPases in Regulation of Cancer Cell Motility, Invasion, and Microenvironment

A. Cox, J. Alan, Donita C. Brady, 2010 .

The role of wild type RAS isoforms in cancer.

C. Der, Bingying Zhou, A. Cox, 2016, Seminars in cell & developmental biology.

Rasosomes originate from the Golgi to dispense Ras signals

Y. Kloog, A. Cox, U. Ashery, 2013, Cell Death and Disease.

The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.

Stephen A. Allsop, J. Yeh, A. Baines, 2011, Carcinogenesis.

ANTI-RAS STRATEGIES FOR CANCER TREATMENT

C. Der, A. Cox, J. Fiordalisi, 2006 .

Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.

C. Der, A. Baines, J. M. Shields, 2006, Methods in enzymology.

Inhibitors of chronically active ras: potential for treatment of human malignancies.

Y. Kloog, A. Cox, R. Blum, 2008, Recent patents on anti-cancer drug discovery.

PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.

C. Thompson, A. Cox, I. Pérez de Castro, 2006, Molecular cell.

Requirement For C-terminal Sequences in Regulation of Ect2 Guanine Nucleotide Exchange Specificity and Transformation*

C. Der, K. Rossman, J. Sondek, 2004, Journal of Biological Chemistry.

Angiotensin II stimulates calcium-dependent activation of c-Jun N-terminal kinase

A. Cox, H. Earp, I. Zohn, 1995, Molecular and cellular biology.

R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl- 2 suppressible mechanism

John Calvin Reed, C. Der, H. G. Wang, 1995, The Journal of cell biology.

Differential Requirement of CAAX-mediated Posttranslational Processing for Rheb Localization and Signaling

F. Tamanoi, C. Der, E. Henske, 2009, Oncogene.

TC21 causes transformation by Raf-independent signaling pathways

Jonathan A. Cooper, C. Der, A. Cox, 1996, Molecular and cellular biology.

Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

M. Shipitsin, C. Der, A. Baines, 2005, Cancer cell.

Biological assays for Ras transformation.

C. Der, A. Cox, G. Clark, 1995, Methods in enzymology.

Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases.

D. Brenner, M. Karin, C. Der, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

C. Der, K. Kato, A. Cox, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.

Theresa M. Grana, A. Cox, C. Sartor, 2002, Cancer research.

The Transforming Rho Family GTPase Wrch-1 Disrupts Epithelial Cell Tight Junctions and Epithelial Morphogenesis

A. Cox, J. Alan, A. Fanning, 2008, Molecular and Cellular Biology.

Oncogenic synergism between ErbB1, nucleolin, and mutant Ras.

P. Bates, Y. Kloog, A. Cox, 2011, Cancer research.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

E. Petricoin, A. Maitra, K. Wennerberg, 2016, Cancer cell.

Rac3-mediated transformation requires multiple effector pathways.

M. Wing, A. Cox, Patricia J. Keller, 2005, Cancer research.

Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance.

Theresa M. Grana, A. Cox, C. Sartor, 2003, Cancer research.

Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling.

A. Cox, Patricia L. Joyce, 2003, Cancer research.

Redox regulation of Rac1 by thiol oxidation.

Xian Chen, H. Gunawardena, A. Cox, 2015, Free radical biology & medicine.

Guanine nucleotide exchange factors: Activators of Ras superfamily proteins

C. Der, R. Khosravi‐Far, A. Cox, 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein

C. Der, A. Cox, J. Buss, 1992, Molecular and cellular biology.

Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.

Y. Kloog, A. Cox, 2004, Seminars in cancer biology.

Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth

C. Der, S. Sebti, A. Hamilton, 2007, Molecular and Cellular Biology.

Effector recruitment method to study spatially regulated activation of Ras and Rho GTPases.

A. Cox, Molly J Decristo, L. P. Huff, 2014, Methods in molecular biology.

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

Michael J. Emanuele, Laura E. Herring, S. Frye, 2019, Science Signaling.

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*)

C. Der, S. Sebti, A. Hamilton, 1995, The Journal of Biological Chemistry.

INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma

Brian D. Bennett, D. Fargo, Yan Zhang, 2016, Genes & development.

Transforming Activity of the Rho Family GTPase, Wrch-1, a Wnt-regulated Cdc42 Homolog, Is Dependent on a Novel Carboxyl-terminal Palmitoylation Motif*

C. Der, A. Cox, A. Minden, 2005, Journal of Biological Chemistry.

Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor

Y. Kloog, A. Cox, L. Lindenboim, 2004, Cell Death and Differentiation.

Targeting RAS-mutant cancers: is ERK the key?

C. Der, A. Cox, A. Wang-Gillam, 2015, Trends in cancer.

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

C. Der, A. Cox, M. Philips, 2015, Clinical Cancer Research.

Geranylgeranyltransferase I as a target for anti-cancer drugs.

A. Cox, M. Philips, Adrienne D Cox, 2007, The Journal of clinical investigation.

INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer

Brian D. Bennett, G. Hu, D. Fargo, 2017, Oncogene.

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer

Laura E. Herring, E. Petricoin, C. Der, 2021, The Journal of biological chemistry.

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer.

E. Petricoin, C. Der, P. Roberts, 2022, Cancer research.

The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation.

C. Miller, C. Der, Jinsong Liu, 2013, Genes & cancer.

Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers.

C. Der, A. Cox, J. Ting, 2023, Cancer discovery.

Farnesyltransferase inhibitors: promises and realities.

Channing J Der, C. Der, A. Cox, 2002, Current opinion in pharmacology.

Farnesyltransferase and Geranylgeranyltransferase Inhibitors

C. Der, A. Cox, J. Fiordalisi, 2000 .

Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases*

T. Elston, C. Der, M. Nishida, 2015, The Journal of Biological Chemistry.

Molecular and Cellular Pathobiology Oncogenic Synergism between ErbB 1 , Nucleolin , and Mutant Ras

P. Bates, Y. Kloog, A. Cox, 2011 .

Radiosensitization of Epidermal Growth Factor Receptor/HER2–Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

J. Tepper, B. Calvo, J. M. Shields, 2010, Clinical Cancer Research.

Atypical Mechanism of Regulation of the Wrch-1 Rho Family Small GTPase

C. Der, A. Cox, Anastacia C. Berzat, 2004, Current Biology.

Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma*

D. Morrison, C. Der, Bingying Zhou, 2016, The Journal of Biological Chemistry.

Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer

Laura E. Herring, E. Petricoin, C. Der, 2021, bioRxiv.

Endothelial Cells Contain a Glycine-Gated Chloride Channel

I. Rusyn, A. Cox, R. Thurman, 2001, Nutrition and cancer.

Use of Caenorhabditis elegans to evaluate inhibitors of Ras function in vivo.

C. Der, A. Cox, V. González-Pérez, 2008, Methods in enzymology.

Up-front polytherapy for ALK-positive lung cancer

Bingying Zhou, A. Cox, 2015, Nature Medicine.

The C. elegans Chp/Wrch Ortholog CHW-1 Contributes to LIN-18/Ryk and LIN-17/Frizzled Signaling in Cell Polarity

C. Der, A. Cox, D. Reiner, 2015, PloS one.

PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.

A. Cox, J. Fiordalisi, Patricia J. Keller, 2006, Cancer research.

Filling in the GAPs in understanding RAS

C. Der, A. Cox, 2021, Science.

Farnesyltransferase inhibitors: Anti-Ras drugs for cancer treatment

C. Der, S. Sebti, A. Hamilton, 1996 .

The ras/cholesterol connection: implications for ras oncogenicity.

C. Der, A. Cox, C J Der, 1992, Critical reviews in oncogenesis.

Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma.

C. Der, A. Cox, A. Fields, 2017, Cancer cell.

Regulation of the Rho Family Small GTPase Wrch-1/RhoU by C-Terminal Tyrosine Phosphorylation Requires Src

A. Cox, L. Graves, J. Alan, 2010, Molecular and Cellular Biology.

Development of a nanotechnology based low-LET multi-microbeam array single cell irradiation system.

O. Zhou, A. Cox, D. Bordelon, 2006, Radiation protection dosimetry.

Radiation Resistance RIE-1 Cells Transformed by the Ras Oncogene Enhances Epidermal Growth Factor Receptor Autocrine Signaling in Updated Version

Theresa M. Grana, A. Cox, C. Sartor, 2003 .

Silencing the killers: paracrine immune suppression in pancreatic cancer.

K. Olive, A. Cox, 2012, Cancer Cell.

Rho GTPases, oxidation, and cell redox control

Bingying Zhou, A. Cox, S. Campbell, 2014, Small GTPases.

The RAF inhibitor paradox revisited.

C. Der, A. Cox, 2012, Cancer cell.

Functional proteomics analysis of GTPase signaling networks.

G. Alton, J. Westwick, A. Cox, 2001, Methods in enzymology.

Engineering threshold-based selection systems

C. Der, A. Cox, V. González-Pérez, 2021, bioRxiv.

RalA and RalBP 1 regulate mitochondrial fission at mitosis

A. Cox, K. Lim, David F. Kashatus, 2011 .

Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration*

G. Bepler, S. Nicosia, C. Der, 2013, Journal of Biological Chemistry.

The raf inhibitor paradox: unexpected consequences of targeted drugs.

C. Der, A. Cox, 2010, Cancer cell.

Biochemical analyses of the Wrch atypical Rho family GTPases.

C. Der, A. Cox, Anastacia C. Berzat, 2006, Methods in enzymology.

Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.

M. Barbacid, C. Der, B. Seizinger, 1995, Oncogene.

VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

C. Der, A. Cox, C. Vaziri, 2023, Genes & cancer.

Guanine Nucleotide Exchange Ras Superfamily Proteins AND DEVELOPMENT 42468-476 ( 1995 ) Factors : Activators of

Channing, R. Khosravi‐Far, A. Cox, 2005 .

The raf inhibitor paradox: unexpected consequences of targeted drugs.

C. Der, A. Cox, 2010, Cancer cell.

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

James M. McFarland, Laura E. Herring, Yingyao Zhou, 2021, Cell reports.

Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma.

C. Der, A. Cox, A. Fields, 2017, Cancer cell.

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

E. Petricoin, P. Singh, C. Der, 2019, Nature Medicine.

C. Der, A. Cox, Timothy D. Martin, 2010 .